Edition:
United Kingdom

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

60.71USD
23 May 2019
Change (% chg)

$-1.38 (-2.22%)
Prev Close
$62.09
Open
$61.42
Day's High
$61.42
Day's Low
$59.60
Volume
71,445
Avg. Vol
132,296
52-wk High
$65.55
52-wk Low
$29.17

Coric, Vlad 

Mr. Vlad Coric, M.D., serves as Chief Executive Officer, Director of Biohaven Pharmaceutical Holding Company Limited. From January 2007 to September 2015, he served as a group director of global clinical research at Bristol-Myers Squibb Company, or BMS, focusing both in oncology global clinical research and neuroscience global clinical research. He has been involved in multiple drug development programs including marketed drugs such as Abilify (aripiprazole; partial dopamine agonist), Opdivo (nivolumab; anti-PD1), Yervoy (Ipilimumab; anti-CTLA-4), Daklinza (daclatasvir; NS5A inhibitor) and Sunvepra (asunaprevir; NS3 inhibitor). Since July 2001, Dr. Coric has also continued to serve as an associate clinical professor of psychiatry at Yale School of Medicine. He previously served as the chief of the Yale Clinical Neuroscience Research Unit and the director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as president of the Connecticut Psychiatric Society. Dr. Coric received his M.D. from Wake Forest University School of Medicine. He completed his internship at Yale-New Haven Hospital and residency training at the Yale Psychiatry Residency Training Program, where he also served as the program-wide chief resident for the Yale Department of Psychiatry, and chief resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric was an honors scholar in neurobiology and physiology at the University of Connecticut where he received a B.S. degree.

Basic Compensation

Total Annual Compensation, USD 3,844,860
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 10,800
Fiscal Year Total, USD 3,855,660

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan

247,770

Vlad Coric

3,855,660

James Engelhart

2,510,280

Charles Conway

1,626,150

Kimberly Gentile

--

Robert Berman

521,060
As Of  31 Dec 2017